Commercialization


  • Thorny issues in pharma
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues

    Rare disease treatments, drug shortages, a market monopoly and march-in rights all play a role in the story of newly revived litigation against Sanofi’s Genzyme.

    By Alexandra Pecci • Feb. 26, 2024
  • blue dosing pen for semaglutide
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Ozempic for liver disease? Weight loss drugs could have even more to offer

    GLP-1 drugs indications could expand as research shows potential benefits in treating MASH, where pharma has failed in the past.

    By Kelly Bilodeau • Feb. 26, 2024
  • An illustration of red blood cells
    Image attribution tooltip
    ismagilov via Getty Images
    Image attribution tooltip

    BioMarin preaches patience amid slow sales for hemophilia gene therapy

    The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.

    By Ben Fidler • Feb. 23, 2024
  • A man in a suit looking at the camera
    Image attribution tooltip
    Courtesy of Biogen
    Image attribution tooltip

    The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround

    A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.

    By Feb. 15, 2024
  • Drug pill question
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    These 4 drugs had tons of promise — and they flopped. What happened?

    No amount of excitement can prevent failures stemming from safety, efficacy, cost and other speed bumps along the way.

    By Alexandra Pecci • Feb. 13, 2024
  • vials
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 questions hanging over the Novo-Catalent deal

    As backlash builds for the recently announced matchup, critical questions remain over its impact.

    By Kelly Bilodeau • Feb. 13, 2024
  • syringe dollar sign shadow
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Could Novo, Lilly become first trillion-dollar healthcare companies?

    Explosive demand for weight loss drugs has propelled both companies to new heights. Here’s a look at the staggering growth, by the numbers.

    By Feb. 2, 2024
  • pill explosion
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    10 of our most read articles in 2023

    A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.

    By Dec. 22, 2023
  • blockbuster drugs
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    What are pharma’s next blockbusters?

    In a shifting market focused on targeted therapeutics, drugs that generate big profits are still a priority.

    By Kelly Bilodeau • Dec. 20, 2023
  • Professional photo of Adam Lenkowsky
    Image attribution tooltip
    Permission granted by Adam Lenkowsky
    Image attribution tooltip
    Q&A

    Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next

    Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.

    By Dec. 12, 2023
  • A sign showing Gilead's logo
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    Patients who hide pills and advocacy offices that could get ‘raided’ — a Gilead leader on navigating global HIV

    Gilead Sciences’ SVP of global patient solutions discusses how she’s managing some of the world’s most complicated health issues and what’s next in HIV innovation.

    By Alexandra Pecci • Dec. 11, 2023
  • A sickle cell and normal blood cells are seen in red against a blue background in this colorized microscope image.
    Image attribution tooltip

    Janice Haney Carr/CDC/Sickle Cell Foundation of Georgia/AP

    Image attribution tooltip
    Deep Dive

    What if a CRISPR cure isn’t such an easy choice?

    A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.

    By Ned Pagliarulo , Nov. 9, 2023
  • Ampoules of Novavax's COVID-19 vaccine prepared in Berlin, Germany.
    Image attribution tooltip
    Carsten Koall/Getty Images via Getty Images
    Image attribution tooltip

    What’s next for COVID dark horse Novavax?

    Novavax scored a new COVID vaccine go-ahead for the 2023-24 season, but is it the boost the company needs?

    By Kelly Bilodeau • Oct. 30, 2023
  • Adele Gulfo Red Jacket header
    Image attribution tooltip
    Permission granted by Sumitomo Pharma America
    Image attribution tooltip
    Q&A // Red Jacket winners 2023

    Red Jacket: Adele Gulfo, a commercialization guru

    With a knack for melding science and patient-focused marketing techniques, the CEO of the biopharma commercial unit at Sumitomo Pharma America has notched blockbuster successes throughout her career.

    By Karissa Waddick • Oct. 27, 2023
  • a blue megaphone stands out among a crowd of orange megaphones against an orange backdrop
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 marketing tips for biotechs emerging from stealth

    In a crowded biotech market, here’s how your company can stand out to investors.

    By Karissa Waddick • Oct. 6, 2023
  • A megaphone tinted purple
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    PharmaVoice 100s: Brand and commercialization pros

    Leaders decoding the complex language of drug development to push treatments past the finish line and into patients’ hands.

    By Karissa Waddick • Oct. 4, 2023
  • Business people leaning over a table together analyzing charts and graphs.
    Image attribution tooltip
    Tinnakorn Jorruang via Getty Images
    Image attribution tooltip

    How pharma marketers can reclaim the drug pricing narrative

    As Medicare negotiations heat up, it’s more important than ever for pharma companies to communicate their value. Here’s how.

    By Karissa Waddick • Sept. 28, 2023
  • Abstract header image of Phil Inc.
    Image attribution tooltip
    Permission granted by Phil Inc
    Image attribution tooltip
    Sponsored by Phil Inc

    Optimizing your hub services program with a gross-to-net lens

    In today’s Biopharma landscape, considering Gross-to-Net is essential for effectively designing and optimizing patient support programs.

    Sept. 25, 2023
  • Opioids, pills, syringe
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A

    As the opioid crisis seethes, a long-lasting treatment could offer new ammunition

    Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.

    By Sept. 21, 2023
  • Pharma five-year plan
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’

    Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.

    By Sept. 15, 2023
  • Actor Ice T puts hands up in the air.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    O.G. Ice-T teams up with Sanofi in horror-themed flu vax ad

    The French pharma’s latest vaccine campaign aims to raise awareness about the flu’s complications for marginalized groups. 

    By Karissa Waddick • Sept. 14, 2023
  • Close up of a machine with several tubes, some of which are red.
    Image attribution tooltip
    saengsuriya13 via Getty Images
    Image attribution tooltip
    Q&A

    In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.

    Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.

    By Sept. 14, 2023
  • CSL Seqirus influenza vaccine being prepared in the lab.
    Image attribution tooltip
    Permission granted by CSL Seqirus
    Image attribution tooltip

    Finding the right flu vaccine is hard. Getting people to take it is harder.

    Experts have determined the strains of this year’s flu season — now the question is whether people are too fatigued by the pandemic to be immunized.

    By Aug. 30, 2023
  • A white pill bottle, pills and a measuring tap sit on a dish on top of a yellow table
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Are weight loss drugs a win for the global economy?

    As Novo Nordisk’s drug Wegovy sways Denmark’s economy, we're examining wider implications for the weight loss market. 

    By Karissa Waddick • Aug. 28, 2023
  • Henrietta Lacks
    Image attribution tooltip

    Steve Ruark/AP

    Image attribution tooltip

    Henrietta Lacks’ immortal cells put biopharma profits under a microscope

    The HeLa cell line’s contributions to medical science were obtained without permission, and now biotechs profiting from its use are answering for it.

    By Aug. 23, 2023